Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight people with type 1 diabetes

Abstract

Aims To investigate the effects of 24 weeks of treatment with liraglutide added to basal/bolus insulin on energy intake, appetite sensations and eating behaviours in overweight/obese participants with type 1 diabetes. Methods In a double‐blinded cross‐over fashion, 15 participants were randomly assigned (1:1) to receive placebo or liraglutide for 24 weeks including a 1‐month titration period from 0.6 to 1.2 to 1.8 mg, in addition to their insulin. The treatment was followed by a 1‐month wash‐out period. Participants were then assigned to the other treatment for another 24 weeks. Food intake was measured, visual analogue scales and Three Factor Eating Questionnaires were completed. Paired rank tests were used to compare the parameters. Results When treated with liraglutide, participants modified their ad libitum food consumption with decreased total intake and % fat and increased carbohydrates. Their appetite sensations were modified: fasting desire to eat, hunger and prospective food consumption were significantly reduced. The sensation of fullness was prolonged for a few hours after a standardized breakfast. Restraint and disinhibition were significantly reduced by liraglutide. Conclusions In this randomized clinical trial, the addition of liraglutide to basal/bolus insulin therapy for 24 weeks in overweight/obese individuals with type 1 diabetes improved significantly their food consumption, appetite sensations and eating behaviours. Clinical Trials.gov No: NCT01787916.